Cargando…

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder involving multicentric lymphadenopathy, systemic inflammation, and cytokine-driven organ dysfunction. Despite the approval of siltuximab, a monoclonal antibody against interleukin-6, for the treatment of iMCD, it is no...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rhee, Frits, Rosenthal, Adam, Kanhai, Karan, Martin, Rabecka, Nishimura, Katherine, Hoering, Antje, Fajgenbaum, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631655/ https://www.ncbi.nlm.nih.gov/pubmed/35793409 http://dx.doi.org/10.1182/bloodadvances.2022007112

Ejemplares similares

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Characteristics of circulating KSHV-infected viroblasts during active KSHV(+) multicentric Castleman disease
por: Martin de Frémont, Gregoire, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
por: McNerney, Kevin O., et al.
Publicado: (2023)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model
por: Rafiei Hashtchin, Anna, et al.
Publicado: (2021)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
por: van Rhee, Frits, et al.
Publicado: (2015)

Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
por: Sitenga, Jenna, et al.
Publicado: (2018)

The histone methyltransferase MLL1/KMT2A in monocytes drives coronavirus-associated coagulopathy and inflammation
por: Sharma, Sriganesh B., et al.
Publicado: (2023)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Catch those antibodies before they fall
por: Shaz, Beth H., et al.
Publicado: (2020)

Expanding the toolbox to combat a pandemic
por: Prockop, Susan E.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
por: Martín Merinero, Hector, et al.
Publicado: (2021)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice
por: Pletinckx, Katrien, et al.
Publicado: (2022)

Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis
por: Huang, Frank Y., et al.
Publicado: (2022)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases
por: Martin Merinero, Héctor, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome
por: Kumar, Deepak, et al.
Publicado: (2022)

Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
por: Tamaki, Masaharu, et al.
Publicado: (2022)

4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
por: Swatler, Julian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ge3f7k5h0m1ckcim6s49lhmo9